1. Home
  2. News
  3. Invex Therapeutics Ltd.
  4. Global Phase 3 Trial of Presendin to Launch in Q4 2021
More Invex Therapeutics Ltd. news
Invex Therapeutics Ltd.ASX: IXC

Global Phase 3 Trial of Presendin to Launch in Q4 2021

Nov 3, 2021 at 10:33 PM EDT · Issued by Invex Therapeutics Ltd.

Filed with ASX · Nov 3, 2021 at 10:33 PM EDT · 5 pages · English

On 6ix: 6ix.com/news/global-phase-3-trial-of-presendin-to-launch-in-q4-2021

Invex Therapeutics Ltd. on 6ix

Story so far

  • Initial FDA and EMA Advice on Presendin DevelopmentJul 23, 2020
  • Exenatide Meets Key Endpoints in IIH Clinical TrialMay 20, 2020

Earlier from Invex Therapeutics

  • Notice of Investor Call and PresentationSep 27, 2021
  • Exclusive Collaboration and Manufacturing AgreementSep 27, 2021
  • Appendix 4E and Annual ReportAug 26, 2021
  • Invex Granted Key European Patent for ExenatideAug 16, 2021
  • Invex Receives Written Response from FDA on Type C MeetingJun 14, 2021

Later from Invex Therapeutics

  • Invex Therapeutics: Chairman's Address to Shareholders at AGMNov 25, 2021
  • Appointment IIH EVOLVE Phase III Trial Steering Group ChairDec 16, 2021
  • New Executive Director and Chairman AgreementsJan 30, 2022
  • Half Yearly Report and AccountsFeb 22, 2022
  • Invex Receives UK Approval to Commence Phase III TrialJun 28, 2022
All Invex Therapeutics news releases↗

Follow Invex Therapeutics into a list and get an email when it puts out news.

Follow Invex Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer